Hirose Koichi, Takahashi Kentaro, Nakajima Hiroshi
Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chiba City, Chiba 260-8670, Japan.
J Allergy (Cairo). 2013;2013:260518. doi: 10.1155/2013/260518. Epub 2013 Feb 21.
IL-23- and IL-17A-producing CD4(+) T cell (Th17 cell) axis plays a crucial role in the development of chronic inflammatory diseases. In addition, it has been demonstrated that Th17 cells and their cytokines such as IL-17A and IL-17F are involved in the pathogenesis of severe asthma. Recently, IL-22, an IL-10 family cytokine that is produced by Th17 cells, has been shown to be expressed at the site of allergic airway inflammation and to inhibit allergic inflammation in mice. In addition to Th17 cells, innate lymphoid cells also produce IL-22 in response to allergen challenge. Functional IL-22 receptor complex is expressed on lung epithelial cells, and IL-22 inhibits cytokine and chemokine production from lung epithelial cells. In this paper, we summarize the recent progress on the roles of IL-22 in the regulation of allergic airway inflammation and discuss its therapeutic potential in asthma.
产生白细胞介素-23(IL-23)和白细胞介素-17A(IL-17A)的CD4(+) T细胞(Th17细胞)轴在慢性炎症性疾病的发展中起关键作用。此外,已有研究表明,Th17细胞及其细胞因子如IL-17A和IL-17F参与了重症哮喘的发病机制。最近,由Th17细胞产生的白细胞介素-10家族细胞因子IL-22已被证明在过敏性气道炎症部位表达,并能抑制小鼠的过敏性炎症。除了Th17细胞外,固有淋巴细胞在受到过敏原攻击时也会产生IL-22。功能性IL-22受体复合物在肺上皮细胞上表达,IL-22可抑制肺上皮细胞产生细胞因子和趋化因子。在本文中,我们总结了IL-22在调节过敏性气道炎症中的作用的最新进展,并讨论了其在哮喘治疗中的潜力。